Real‐world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high‐risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry

This publication has 12 references indexed in Scilit:

• High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing
  Blood, 2026
• Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma
  Blood, 2025
• Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients
  Blood, 2025
• European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma
  American Journal of Hematology, 2025
• International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
  Journal of Clinical Oncology, 2025
• Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
  American Society of Clinical Oncology Educational Book, 2024
• The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)
  Clinical Lymphoma Myeloma and Leukemia, 2021
• Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma
  British Journal of Haematology, 2020
• A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
  Leukemia, 2019
• Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry
  BMC Medical Research Methodology, 2016